7 research outputs found

    ΠžΠΏΡ‚ΠΈΠΌΠΈΠ·Π°Ρ†ΠΈΡ лапароскопичСской ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊΠΈ лСчСния Ρ‚Π΅Ρ€Π°Ρ‚ΠΎΠΌΡ‹ яичника Ρƒ ΠΆΠ΅Π½Ρ‰ΠΈΠ½ Ρ€Π΅ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΈΠ²Π½ΠΎΠ³ΠΎ возраста

    Get PDF
    Π’ экспСримСнтС ΠΈ клиничСскими исслСдованиями ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ влияниС Π»ΡƒΡ‡Π΅Π²ΠΎΠΉ Π°Ρ€Π³ΠΎΠ½ΠΎΠ²ΠΎΠΉ коагуляции, биполярной коагуляции ΠΈ эндоскопичСского ΡƒΡˆΠΈΠ²Π°Π½ΠΈΡ яичников ΠΊΠ΅Ρ‚Π³ΡƒΡ‚ΠΎΠΌ ΠΏΡ€ΠΈ лапароскопичСском Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π΄Π΅Ρ€ΠΌΠΎΠΈΠ΄Π½Ρ‹Ρ… кист яичников Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠΊ с бСсплодиСм Π½Π° Π΄Π°Π»ΡŒΠ½Π΅ΠΉΡˆΡƒΡŽ ΠΈΡ… Ρ€Π΅ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΈΠ²Π½ΡƒΡŽ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΡŽ ΠΈ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ спаСчного процСсса Π² послСопСрационном ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅.The influence of argon coagulation, bipolar coagulation and endoscopic suture of ovaries with catgut at laparoscopic treatment for dermoid ovarian cysts in infertile patients on the further reproductive function and development of adhesions after the surgery were investigated experimentally and clinically

    Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? : The example of haloperidol

    No full text
    PURPOSE: Monitoring of the QT duration by electrocardiography (ECG) prior to treatment is frequently recommended in the label of QT-prolonging drugs. It is, however, unknown how often general practitioners in daily clinical practice are adhering to these risk-minimization measures. We assessed the frequency of ECG measurements in patients where haloperidol was initiated in primary care. METHODS: Patients (β‰₯18 years) with a first prescription of haloperidol in the UK Clinical Practice Research Datalink (2009-2013) were included. The proportion of ECGs made was determined in two blocks of 4 weeks: during the exposure period when haloperidol was initiated, and during the control period, 1 year before. Conditional logistic regression analysis was applied to calculate the relative risk of having an ECG in the exposure period compared with the control period. Subgroup analyses were performed to assess the proportion of ECG measurements in patients with one or more additional risk factors for QT prolongation. RESULTS: In total, 3420 patients were prescribed haloperidol during the exposure period, and 1.8% of them had an ECG at treatment initiation, compared with 0.8% during the control period (relative risk [RR] 2.4 [1.5-3.8]). Of the patients with additional risk factors for QT prolongation, 1.9% of the patients had an ECG at initiation of the prescription, compared with 1.0% during the control period (RR 2.1 [1.2-3.5]). CONCLUSIONS: Compliance with recommendations to perform an electrocardiogram when starting a new QT-prolonging drug is extremely low, when haloperidol is taken as an example

    Flow chart.

    No full text
    <p>The source region had a population of 2 426 097 people in 2007 [Netherlands Statistics. <a href="http://statline.cbs.nl/" target="_blank">http://statline.cbs.nl/</a>. Accessed May 15, 2010].</p

    Obstructive pulmonary disease and the risk of sudden cardiac arrest stratified by age group, sex and cardiovascular risk profile<sup>1</sup>.

    No full text
    <p>Data are number (%). CI: confidence interval, CVD: cardiovascular disease, N: number, n/a: not applicable, OPD: obstructive pulmonary disease, OR: odds ratio.</p>1<p>Use of Ξ²- adrenoreceptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, diuretics, angiotensin-II receptor blockers, nitrates, platelet aggregation inhibitors, and/or statins within six months prior to index date.</p>2<p>Adjusted for cardiovascular risk profile.</p>3<p>Interaction on a multiplicative scale: OR 1.1 (0.7–1.6), on an additive scale: synergy index 1.4 (0.7–2.6).</p

    Determinants of risk of sudden cardiac arrest.

    No full text
    <p>CI: confidence interval, OR: odds ratio.</p>1<p>Adjusted for all potential confounders.</p>2<p>Adjusted for all covariates that were univariately associated with sudden cardiac arrest.</p>3<p>Adjusted for all covariates that were univariately associated with sudden cardiac arrest and changed the beta with at least 5%.</p>4<p>Use of any of the following drugs: Ξ²-adrenoreceptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, diuretics, angiotensin-II receptor blockers, nitrates, platelet aggregation inhibitors, and/or statins, within six months prior to index date.</p>5<p>Use of anti-diabetics within six months prior to index date.</p>6<p>Class I and III antiarrhythmic drugs and non-antiarrhythmic drugs with (possible) risk of QT prolongation. (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0065638#pone.0065638.s001" target="_blank">Table S1</a>).</p

    Baseline characteristics of the study population.

    No full text
    <p>Data are number (%) unless otherwise indicated. OPD: obstructive pulmonary disease.</p>1<p>Drug use at index date.</p>2<p>Drug use at index date, or within six months prior to index date.</p>3<p>Use of systemic corticosteroids with a duration of 90 days or more.</p>4<p>Use of any of the following drugs: Ξ²-adrenoreceptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, diuretics, angiotensin-II receptor blockers, nitrates, platelet aggregation inhibitors, and statins, within six months prior to index date.</p>5<p>Use of anti-diabetics within six months prior to index date.</p>6<p>Class I and III antiarrhythmic drugs and non-antiarrhythmic drugs with (possible) risk of QT prolongation (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0065638#pone.0065638.s001" target="_blank">Table S1</a>).</p
    corecore